To manufacture and test the COVID-19 vaccine Corbett's team partnered with Moderna, a biotechnology company, to rapidly enter animal studies. Subsequently, the vaccine entered Phase 1 clinical trial only 66 days after the virus sequence was released. The trial, to be completed in at least 45 people, is a dose escalation study in the form of two injections separated by 28 days.[15]Corbett's work afforded her the opportunity to be a part of the National Institutes of Health team that welcomed Donald Trump to the Dale and Betty Bumpers Vaccine Research Center in March 2020.[3][16]